Detalhe da pesquisa
1.
Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis.
Br J Haematol
; 204(5): 1882-1887, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38501390
2.
Overcoming T-cell exhaustion in LCH: PD-1 blockade and targeted MAPK inhibition are synergistic in a mouse model of LCH.
Blood
; 137(13): 1777-1791, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33075814
3.
Prevalence of the BRAF V600E mutation in Greek adults with Langerhans cell histiocytosis.
Pediatr Hematol Oncol
; 39(6): 540-548, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35139731
4.
Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis.
Blood
; 132(1): 89-100, 2018 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29632024
5.
CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions.
Cancer
; 124(12): 2607-2620, 2018 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29624648
6.
Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis.
Blood
; 128(21): 2533-2537, 2016 11 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-27729324
7.
Primary immunodeficiency diseases: Genomic approaches delineate heterogeneous Mendelian disorders.
J Allergy Clin Immunol
; 139(1): 232-245, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27577878
8.
Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.
Blood
; 124(19): 3007-15, 2014 Nov 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-25202140
9.
Differentiating skin-limited and multisystem Langerhans cell histiocytosis.
J Pediatr
; 165(5): 990-6, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25441388
10.
A genome-wide association study of LCH identifies a variant in SMAD6 associated with susceptibility.
Blood
; 130(20): 2229-2232, 2017 11 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-28935696
11.
Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children's Oncology Group study.
Blood Adv
; 8(5): 1116-1127, 2024 Mar 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38163318
12.
BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology.
Nat Med
; 27(5): 851-861, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33958797
13.
IFN-γ signature in the plasma proteome distinguishes pediatric hemophagocytic lymphohistiocytosis from sepsis and SIRS.
Blood Adv
; 5(17): 3457-3467, 2021 09 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34461635
14.
Circulating CD1c+ myeloid dendritic cells are potential precursors to LCH lesion CD1a+CD207+ cells.
Blood Adv
; 4(1): 87-99, 2020 01 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31899802
15.
Defining the Inflammatory Plasma Proteome in Pediatric Hodgkin Lymphoma.
Cancers (Basel)
; 12(12)2020 Dec 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33276546
16.
Cellular distribution of mutations and association with disease risk in Langerhans cell histiocytosis without BRAFV600E.
Blood Adv
; 6(16): 4901-4904, 2022 08 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-35816634
17.
Activating MAPK1 (ERK2) mutation in an aggressive case of disseminated juvenile xanthogranuloma.
Oncotarget
; 8(28): 46065-46070, 2017 Jul 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28512266
18.
Survivin-specific T cell receptor targets tumor but not T cells.
J Clin Invest
; 125(1): 157-68, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25415440
19.
BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups.
J Exp Med
; 211(4): 669-83, 2014 Apr 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-24638167
20.
BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups.
J Exp Med
; 212(2): 281, 2015 Feb 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-25646268